Skip to main content

Table 2 Baseline demographics and clinical characteristics

From: Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

  Safety population (n = 351) Faster infusion evaluable populationa(n = 337)
Demographics
Female, n (%) 279 (79.5) 268 (79.5)
Age, mean (SD), y 55.5 (11.5) 55.6 (11.4)
  Range 23-88 23-88
Age group, n (%)   
  18-40 y 38 (10.8) 34 (10.1)
  41-64 y 244 (69.5) 236 (70.0)
  ≥ 65 y 69 (19.7) 67 (19.9)
Race, n (%)   
  White 295 (84.0) 283 (84.0)
  African American 35 (10.0) 33 (9.8)
  Other 21 (6.0) 21 (6.2)
Weight, mean (SD), kg 84.9 (21.2) 84.9 (21.2)
  Range 47-156 47-156
Height, mean (SD), cm 165.0 (9.6) 165.0 (9.6)
  Range 130-198 130-198
RA clinical characteristics
Duration of RA, mean (SD), y 12.5 (9.7) 12.4 (9.6)
RA disease duration, n (%)   
< 3 y 42 (12.0) 42 (12.5)
  3-4 y 39 (11.1) 38 (11.3)
  5-10 y 93 (26.5) 87 (25.8)
> 10 y 177 (50.4) 170 (50.4)
Prior rituximab treatment
No. of prior rituximab courses, n (%)   
  0 306 (87.2) 293 (86.9)
  1 24 (6.8) 24 (7.1)
  2 21 (6.0) 20 (5.9)
Months since most recent rituximab course, n 45 44
  Mean (SD) 6.8 (0.9) 6.7 (0.9)
  Range 5-9 5-9
Medication history
No. of prior anti-TNF agents, n (%)   
  0 4 (1.1) 4 (1.2)
  1 187 (53.3) 182 (54.0)
  2 116 (33.0) 108 (32.0)
  ≥ 3 44 (12.5) 43 (12.8)
Prior non–anti-TNF biologic DMARDs   
  Abatacept 17 (4.8) 16 (4.7)
  Tocilizumab 12 (3.4) 12 (3.6)
MTX dose, mg/wk   
  Mean (SD) 17.4 (4.7) 17.3 (4.7)
  Median (range) 17.5 (8–25) 17.5 (8–25)
Oral steroid use, n (%) 150 (42.7) 143 (42.4)
Oral steroid dose, mg/d   
  Mean (SD) 7.2 (3.4) 7.3 (3.4)
  Median (range) 5 (2–25) 5 (2–25)
  1. Anti-TNF, anti–tumor necrosis factor; DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; SD, standard deviation. aOf the 341 patients who received infusion 2, four were not included because medication volume was not recorded.